AbCellera Biologics (ABCL) Non-Current Deferred Tax Liability (2020 - 2025)

AbCellera Biologics has reported Non-Current Deferred Tax Liability for 6 years, with the latest figure at $9.1 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Deferred Tax Liability fell 85.69% year-over-year to $9.1 million; the trailing twelve-month figure through Dec 2025 stood at $9.1 million (down 85.69% YoY), and the FY2025 full-year result was $9.1 million, down 85.69% from the prior year.
• Non-Current Deferred Tax Liability for Q4 2025 stood at $9.1 million, down from $9.7 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $77.2 million in Q4 2023, with the low at $9.1 million in Q4 2025.
• Historically, Non-Current Deferred Tax Liability has averaged $31.9 million across 5 years, with a median of $33.2 million in 2023.
• Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability soared 65.54% — and 2025, when it slumped 85.69%.
• AbCellera Biologics' Non-Current Deferred Tax Liability stood at $37.4 million in 2021, then soared by 65.54% to $61.9 million in 2022, then increased by 24.65% to $77.2 million in 2023, then decreased by 17.48% to $63.7 million in 2024, then tumbled by 85.69% to $9.1 million in 2025.
• The last three Non-Current Deferred Tax Liability figures came in at $9.1 million (Q4 2025), $9.7 million (Q3 2025), and $10.1 million (Q2 2025), per Business Quant data.